The complexity of cancer chemotherapy requires that pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparing, dispensing, and administering antineoplastic therapy and to the agents, commercially available and investigational, used to treat malignant diseases.
PetrylakD.P., MacarthurR.B., O'ConnorJ.Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol.1999; 17(3): 958–967.
3.
WeitzmanA.L., SheltonG., ZuechN.Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol.2000; 163(3): 834–837.
4.
EasthamJ.A., KellyW.K., GrossfeldG.D.Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology.2003; 62(Suppl 1): 55–62.
5.
NeliusT., ReiherF., LindenmeirT.Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer. Onkologie.2005; 28(11): 573–578.
SavareseD., TaplinM.E., HalabiS.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B Trial 9780. Semin Oncol.1999; 26(5) (suppl 17): 39–44.
8.
SinibaldiV.J., CarducciM., LauferM.Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer. Semin Oncol.1999; 26(5)(suppl 17): 45–48.
9.
SinibaldiV.J., CarducciM.A., Moore-CooperS.Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer.2002; 94(5): 1457–1465.
10.
Sitka CopurM., LedakisP., LynchJ.Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer. Semin Oncol.2001; 28(4) (suppl 15): 16–21.
11.
WalczakJ.R., CarducciM.A.; Eastern Cooperative Oncology Group E1899. Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination che mo therapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study. Urology.2003; 62(Suppl 1): 141–146.
12.
PetrylakD.P., TangenC.M., HussainM.H.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med.2004; 351(15): 1513–1520.
13.
BerryD.L., MoinpourC.M., JiangC.S.; Southwest Oncology Group. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol.2006; 24(18): 2828–2835.
14.
HussainM., SmithD.C., El-RayesB.F.Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology.2003; 61(4): 774–780.
15.
CoccaroM., TartaroneA., RomanoG.Dose-finding study of weekly docetaxel plus estramustine in patients with hormone-refractory metastatic prostate cancer. Tumori.2005; 91(4): 314–316.
16.
HainsworthJ.D., MeluchA.A., SpigelD.R.Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate-specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network. Clin Genitourin Cancer.2006; 4(4): 287–292.
17.
ChittoorS., BerryW., LoeschD.Phase II study of low-dose docetaxel/ estramustine in elderly patients or patients aged 18–74 years with hormone-refractory prostate cancer. Clin Genitourin Cancer.2006; 5(3): 212–218.
18.
CarlesJ., FontA., MelladoB.Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer.2007; 97(9): 1206–1210.
19.
EymardJ.C., PriouF., ZannettiA.Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol.2007; 18(6): 1064–1070.
20.
CaffoO., SavaT., ComplojE.Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int.2008; 102(9): 1080–1085.
21.
TakenakaA., YamadaY., KurahashiT.Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients. Int J Urol.2008; 15(1): 106–109.
22.
National Comprehensive Cancer Network clinical practice guidelines in oncology—prostate cancer. V.2.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org/index.asp. Accessed April 26, 2009.
23.
WinquistE., WaldronT., BerryS.Non-hormonal systemic therapy in men with hormone-refractory prostate cancer: a clinical practice guideline.www.cancercare.on.ca/pdf/pebc3–15s.pdf. Published November 1, 2005. Accessed February 10, 2009.
24.
BaschE.M., SomerfieldM.R., BeerT.M.American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol.2007; 25(33): 5313–5318.
25.
CohenM.R., SmetzerJ.Preparing for a damaging medication error. ISMP Medication Safety Alert!1999; 4(14): 26.
26.
HeskethP.J., KrisM.G., GrunbergS.M.Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol.1997; 15(1): 103–109.
27.
National Comprehensive Cancer Network clinical practice guidelines—antiemesis. V.3.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org/index.asp. Accessed April 26, 2009.
28.
KrisM.G., HeskethP.J., SomerfieldM.R.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol.2006; 24(18): 2932–2947.
GelingO., EichlerH.G.Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005; 23(6): 1289–1294.
31.
TerreyJ.P., AaproM.S.The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996; 8: 281–288.
32.
CarmichaelJ., KeizerH.J., CupissolD.Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998; 9(5): 381–385.
33.
de WitR., de BoerA.C., vd LindenG.H.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001; 85(8): 1099–1101.
34.
SmithI.E.A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993; 119(6): 350–354.
35.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer.1994; 2(3): 177–183.
ZanottiK.M., MarkmanM.Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf.2001; 24(10): 767–779.
38.
SmithT.J., KhatcheressianJ., LymanG.H.2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol.2006; 24(19): 3187–3205.
39.
National Comprehensive Cancer Network clinical practice guidelines in oncology—myeloid growth factors. V.1.2009. National Comprehensive Cancer Network Web site. http://www.nccn.org/index.asp. Accessed February 10, 2009.
40.
LarsonD.L.Treatment of tissue extravasation by antitumor agents. Cancer.1982; 49(9): 1796–1799.
41.
LarsonD.L.What is the appropriate management of tissue extravasation by antitumor agents?Plast Reconstr Surg.1985; 75(3): 397–402.
42.
MullinS., BeckwithM.C., TylerL.S.Prevention and management of antineoplastic extravasation injury. Hosp Pharm.2000; 35(1): 57–74.
43.
KintzelP.E., DorrR.T.Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev.1995; 21(1): 33–64.
44.
AronoffG.R., BennettW.M., BernsJ.S.Drug Prescribing in Renal Failure.5th ed.Philadelphia, PA: American College of Physicians; 2007.
45.
FloydJ., MirzaI., Sachs, PerryM.C.Hepatotoxicity of chemotherapy. Semin Oncol.2006; 33(1): 50–67.
